Celestia S. Higano
Fred Hutchinson Cancer Research Center
465 Papers
3.4K Citations
Celestia S. Higano is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Prostate cancer & Medicine. The author has an hindex of 78, co-authored 423 publications. Previous affiliations of Celestia S. Higano include United States Department of Veterans Affairs & Ohio State University.
Chat about Author
Papers
•Journal Article
Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer. Discussion
Matthew R. Smith,Philip W. Kantoff,Peter R. Carroll,David A. Benaron,William R. Sellers,Celestia S. Higano +5 more
TL;DR: Zoledronic acid decreases the risk of skeletal related events in men with bone metastases and disease progression after first line hormonal therapy and additional clinical research is needed to evaluate the optimal timing, schedule and duration of bisphosphonate treatment inMen with metastatic prostate cancer.
22
Phase III SYNERGY trial: Docetaxel +/- custirsen and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and poor prognosis.
Kim N. Chi,Celestia S. Higano,Brent A. Blumenstein,James A. Reeves,Susan Feyerabend,Gwenaelle Gravis,Jean-Marc Ferrero,Cindy Jacobs,Johann S. de Bono +8 more
TL;DR: To explore the hypothesis that clusterin inhibition may be more relevant in poor prognosis disease, outcomes by prognostic sub-groups retrospectively were evaluated and results included the following main effects: liver mets, opioid use, Karnofsky < 90, PSA, LDH, alk phos, and hemoglobin.
22
ARN-509 in Men with High Risk Non-Metastatic Castration-Resistant Prostate Cancer
Matthew R. Smith,Emmanuel S. Antonarakis,Charles J. Ryan,William R. Berry,Neal D. Shore,Glenn Liu,Joshi J. Alumkal,Celestia S. Higano,E. Chow-Maneval,Dana E. Rathkopf +9 more
TL;DR: In men with high-risk non-metastatic CRPC, ARN-509 is safe and well tolerated with promising preliminary activity based on high PSA response rates.
22
Clinical and immunologic findings in a phase 2 study of a GM-CSF-secreting prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer (met HPRC)
Jonathan W. Simons,Celestia S. Higano,David Smith,John M. Corman,C. Steidle,Marc Gittelman,Gary R. Hudes,J. Aimi,Natalie Sacks,Eric J. Small +9 more
TL;DR: A phase 2 study of allogeneic prostate carcinoma cell lines genetically modified to secrete GM-CSF (GVAX) in 34 met HRPC patients yielded a median survival of 26 months, and clinical activity and safety prior to initiation of phase 3 trials was confirmed.
22
Genetic Profiling to Determine Risk of Relapse-Free Survival in High-Risk Localized Prostate Cancer
Christine M. Barnett,Michael Heinrich,Jeong Lim,Dylan Nelson,Carol Beadling,Andrea Warrick,Tanaya Neff,Celestia S. Higano,Mark Garzotto,David Z. Qian,Christopher L. Corless,George Thomas,Tomasz M. Beer +12 more
TL;DR: Although point mutations alone did not have a statistically significant association with relapse, PTEN loss was associated with an increased relapse in high-risk prostate cancer treated with chemotherapy followed by surgery.
21